Abstract
The application of ATP-loaded liposomes has been shown effective against ischemic damage in several tissues. In this study, we have prepared ATP-containing liposomes capable of specific recognition of component (myosin) specific for ischemic myocardium. ATP-containing immunoliposomes specific towards cardiac myosin were obtained by the attachment of the monoclonal anti-cardiac myosin 2G4 antibody to the surface of ATP-containing PEGylated liposomes prepared by the freezing-thawing method. Since intracellular myosin is exposed only in the areas containing ischemically compromised cells with damaged plasmic membranes, such liposomes are expected to target these areas both in vitro and in vivo. The attachment of the antibody did not provoke their ATP release from the liposomes and only minimally influenced liposome size and size distribution. Liposome-attached anti-myosin 2G4 antibody preserved its specific activity; and anti-myosin antibody-bearing, ATP-loaded liposomes bound efficiently to the monolayer of myosin in ELISA. The preparation of myosin-specific ATP-loaded immunoliposomes represented an important step in the development of targeted delivery systems capable of providing energy support to ischemic myocardium in vivo.
Keywords: atp, liposomes, anti-myosin antibody, immunotargeting, elisa
Current Drug Delivery
Title: ATP-Containing Immunoliposomes Specific for Cardiac Myosin
Volume: 1 Issue: 1
Author(s): Wei Liang, Tatyana Levchenko, Ban-An Khaw and Vladimir Torchilin
Affiliation:
Keywords: atp, liposomes, anti-myosin antibody, immunotargeting, elisa
Abstract: The application of ATP-loaded liposomes has been shown effective against ischemic damage in several tissues. In this study, we have prepared ATP-containing liposomes capable of specific recognition of component (myosin) specific for ischemic myocardium. ATP-containing immunoliposomes specific towards cardiac myosin were obtained by the attachment of the monoclonal anti-cardiac myosin 2G4 antibody to the surface of ATP-containing PEGylated liposomes prepared by the freezing-thawing method. Since intracellular myosin is exposed only in the areas containing ischemically compromised cells with damaged plasmic membranes, such liposomes are expected to target these areas both in vitro and in vivo. The attachment of the antibody did not provoke their ATP release from the liposomes and only minimally influenced liposome size and size distribution. Liposome-attached anti-myosin 2G4 antibody preserved its specific activity; and anti-myosin antibody-bearing, ATP-loaded liposomes bound efficiently to the monolayer of myosin in ELISA. The preparation of myosin-specific ATP-loaded immunoliposomes represented an important step in the development of targeted delivery systems capable of providing energy support to ischemic myocardium in vivo.
Export Options
About this article
Cite this article as:
Liang Wei, Levchenko Tatyana, Khaw Ban-An and Torchilin Vladimir, ATP-Containing Immunoliposomes Specific for Cardiac Myosin, Current Drug Delivery 2004; 1 (1) . https://dx.doi.org/10.2174/1567201043480063
| DOI https://dx.doi.org/10.2174/1567201043480063 |
Print ISSN 1567-2018 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances in Drug Delivery for Modern Dentistry
This special issue of Current Drug Delivery is dedicated to exploring the cutting-edge integration of drug delivery technologies within the field of dentistry. As oral diseases remain among the most prevalent health challenges worldwide, there is an urgent need for innovative, effective, and patient-friendly therapeutic approaches. This issue highlights how ...read more
Advances of Natural Products, Bio-Actives and Novel Drug Delivery System Against Emerging Viral Infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity, and high bioavailability. The most suitable ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Exosome-Based Drug Delivery for Regenerative Medicine
Exosome-based drug delivery is emerging as a transformative technology in regenerative medicine due to exosomes' natural ability to mediate intercellular communication and carry bioactive molecules like proteins, lipids, and nucleic acids. This thematic issue focuses on exosomes as nanocarriers for therapeutic delivery, harnessing their potential to enhance tissue repair, immune ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research Cross-Talk Between NO and Arachidonic Acid in Inflammation
Current Medicinal Chemistry Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease
Current Drug Therapy Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Aminoacid Support in the Prevention of Diabetes and Diabetic Complications
Current Protein & Peptide Science Pharmacological and Cellular Therapies to Prevent Restenosis after Percutaneous Transluminal Angioplasty and Stenting
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in Fluorescent Probes for Monitoring of Hydrogen Sulfide
Current Medicinal Chemistry Anaphylaxis in Risky Populations
Current Pharmaceutical Design Ferulic Acid and Cardiovascular Health: Therapeutic and Preventive Potential
Mini-Reviews in Medicinal Chemistry Chemistry and Biological Activities of Buxus Alkaloids
Current Bioactive Compounds Adeno-associated Virus 9-mediated Small RNA Interference of TLR4 Alleviates Myocardial Ischemia and Reperfusion Injury by Inhibition of the NF-κB and MAPK Signaling Pathways in Rats
Current Molecular Medicine Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Editorial [Hot Topic: The Evolution of Cell Therapy Towards Enhancing Vascular Regeneration in the Clinic (Guest Editors: Drew Kuraitis and Erik J. Suuronen)]
Current Vascular Pharmacology Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry





